- Home
- RY vs MRK Comparison
RY vs MRK Comparison
Compare RY & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RY
- MRK
- Stock Information
- Founded
- RY 1864
- MRK 2000
- Country
- RY Canada
- MRK United States
- Employees
- RY N/A
- MRK N/A
- Industry
- RY
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- RY
- MRK Health Care
- Exchange
- RY Nasdaq
- MRK Nasdaq
- Market Cap
- RY 186.5B
- MRK 218.8B
- IPO Year
- RY N/A
- MRK N/A
- Fundamental
- Price
- RY $145.22
- MRK $86.04
- Analyst Decision
- RY Strong Buy
- MRK Buy
- Analyst Count
- RY 2
- MRK 15
- Target Price
- RY $177.50
- MRK $105.29
- AVG Volume (30 Days)
- RY 1.1M
- MRK 10.1M
- Earning Date
- RY 12-03-2025
- MRK 10-30-2025
- Dividend Yield
- RY 2.98%
- MRK 3.75%
- EPS Growth
- RY 18.99
- MRK 58.06
- EPS
- RY 9.55
- MRK 7.56
- Revenue
- RY $43,552,874,021.00
- MRK $64,235,000,000.00
- Revenue This Year
- RY $25.11
- MRK $1.82
- Revenue Next Year
- RY $3.05
- MRK $5.10
- P/E Ratio
- RY $15.23
- MRK $11.42
- Revenue Growth
- RY 16.26
- MRK 1.68
- 52 Week Low
- RY $106.10
- MRK $73.31
- 52 Week High
- RY $149.44
- MRK $105.07
- Technical
- Relative Strength Index (RSI)
- RY 45.86
- MRK 52.44
- Support Level
- RY $145.07
- MRK $82.01
- Resistance Level
- RY $145.99
- MRK $88.30
- Average True Range (ATR)
- RY 1.60
- MRK 1.97
- MACD
- RY -0.37
- MRK -0.25
- Stochastic Oscillator
- RY 30.36
- MRK 59.22
About RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada, with around CAD 2.2 trillion in assets. It is a diversified financial services company, offering personal and commercial banking, wealth management, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada and has dominant market shares. RBC also has wealth and capital market businesses in the US, UK, and other countries. RBC is a top 15 investment bank globally.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).